{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:53:16Z","timestamp":1780717996801,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejpb.2018.08.006","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T04:24:05Z","timestamp":1534220645000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Biophysical virus particle specific characterization to sharpen the definition of virus stability"],"prefix":"10.1016","volume":"132","author":[{"given":"Didier","family":"Cl\u00e9net","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Vinit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Soulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Guinet-Morlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aure","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2018.08.006_b0005","unstructured":"Guidelines on stability evaluation of vaccines, WHO\/BS\/06.2049, 2006."},{"key":"10.1016\/j.ejpb.2018.08.006_b0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.biologicals.2009.08.009","article-title":"Vaccine stability study design and analysis to support product licensure","volume":"37","author":"Schofield","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2018.08.006_b0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/jps.22812","article-title":"Forced degradation of therapeutic proteins","volume":"101","author":"Hawe","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jps.10296","article-title":"Thermal stability of vaccines","volume":"92","author":"Brandau","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2015.10.016","article-title":"Forced degradation studies of biopharmaceuticals: selection of stress conditions","volume":"98","author":"Tamizi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0030","series-title":"Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases","first-page":"853","article-title":"Practical Approaches to Forced Degradation Studies of Vaccines","author":"Hasija","year":"2016"},{"key":"10.1016\/j.ejpb.2018.08.006_b0035","doi-asserted-by":"crossref","first-page":"10790","DOI":"10.1021\/bi800726m","article-title":"Fitting yeast and mammalian prion aggregation kinetic data with the Finke-Watzky two-step model of nucleation and autocatalytic growth","volume":"47","author":"Watzky","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2018.08.006_b0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbapap.2008.10.016","article-title":"Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature","volume":"1794","author":"Morris","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Prot. Proteomics"},{"key":"10.1016\/j.ejpb.2018.08.006_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0040-6031(71)85051-7","article-title":"Study of the kinetics of the mechanism of solid-state reactions at increasing temperatures","volume":"3","author":"\u0160est\u00e1k","year":"1971","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.ejpb.2018.08.006_b0050","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/jps.24117","article-title":"Advanced kinetic analysis as a tool for formulation development and prediction of vaccine stability","volume":"103","author":"Clenet","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tca.2014.01.005","article-title":"Prediction of thermal stability of materials by modified kinetic and model selection approaches based on limited amount of experimental points","volume":"579","author":"Roduit","year":"2014","journal-title":"Thermochim. Acta"},{"key":"10.1016\/j.ejpb.2018.08.006_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2018.01.005","article-title":"Accurate prediction of vaccine stability under real storage conditions and during temperature excursions","volume":"125","author":"Cl\u00e9net","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0065","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1016\/S1359-0278(98)00002-9","article-title":"Protein aggregation: folding aggregates, inclusion bodies and amyloid","volume":"3","author":"Fink","year":"1998","journal-title":"Fold Des."},{"key":"10.1016\/j.ejpb.2018.08.006_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.11.014","article-title":"Protein aggregation and its inhibition in biopharmaceutics","volume":"289","author":"Wang","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/btpr.1812","article-title":"Protein misfolding and aggregation research: some thoughts on improving quality and utility","volume":"29","author":"Murphy","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ejpb.2018.08.006_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.abb.2011.01.024","article-title":"Bovine Serum Albumin protofibril-like aggregates formation: solo but not simple mechanism","volume":"508","author":"Vetri","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejpb.2018.08.006_b0085","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2174\/138920109788488932","article-title":"Mechanisms of protein aggregation","volume":"10","author":"Philo","year":"2009","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0090","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1074\/jbc.M110.160457","article-title":"Classification and characterization of therapeutic antibody aggregates","volume":"286","author":"Joubert","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejpb.2018.08.006_b0095","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijpharm.2011.03.064","article-title":"Predicting solution aggregation rates for therapeutic proteins: approaches and challenges","volume":"418","author":"Roberts","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1208\/s12248-013-9485-3","article-title":"Non-arrhenius protein aggregation","volume":"15","author":"Wang","year":"2013","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.ejpb.2018.08.006_b0105","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.vaccine.2009.12.025","article-title":"Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices","volume":"28","author":"Renteria","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ejpb.2018.08.006_b0110","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1002\/jps.23243","article-title":"Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products","volume":"101","author":"Marszal","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: Influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.040","article-title":"Immunogenicity of protein aggregates\u2014concerns and realities","volume":"431","author":"Wang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2007.01.011","article-title":"Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization","volume":"363","author":"Denis","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.ejpb.2018.08.006_b0130","doi-asserted-by":"crossref","first-page":"e36996","DOI":"10.1371\/journal.pone.0036996","article-title":"Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa plasmodium falciparum merozoite surface protein-1","volume":"7","author":"Qian","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.08.006_b0135","doi-asserted-by":"crossref","first-page":"8475","DOI":"10.1016\/j.biomaterials.2010.07.068","article-title":"Immune responses to coiled coil supramolecular biomaterials","volume":"31","author":"Rudra","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2018.08.006_b0140","unstructured":"Ph.Eur. 2.9.19 \u2013 Pharmacopoea europaea, sixth ed. Particulate contamination: sub-visible particles, European Directorate For The Quality Of Medicine (EDQM), 2008."},{"key":"10.1016\/j.ejpb.2018.08.006_b0145","unstructured":"Ph.Eur. 2.9.20, Pharmacopoea europaea, sixth ed. Particulate contamination: visible particles. European Directorate For The Quality Of Medicine (EDQM), 2008."},{"key":"10.1016\/j.ejpb.2018.08.006_b0150","unstructured":"USP<788>, United States Pharmacopeia, USP33. Particulate matter in injections. United States Pharmacopeial Convention, 2009."},{"key":"10.1016\/j.ejpb.2018.08.006_b0155","unstructured":"USP<1>, United States Pharmacopeia, USP35-NF30. Injections\/General requirements. United States Pharmacopeial convention, 2012."},{"key":"10.1016\/j.ejpb.2018.08.006_b0160","unstructured":"USP<1787>, United States Pharmacopeia, USP\/NF. Measurement of subvisible particulate matter in therapeutic protein injections, 2015."},{"key":"10.1016\/j.ejpb.2018.08.006_b0165","unstructured":"C.f.D.E.a.R. U.S. Department of Health and Human Services FDA, Center for Biologics Evaluation and Research, Guidance for industry: immunogenicity assessment for therapeutic protein products, 2014."},{"key":"10.1016\/j.ejpb.2018.08.006_b0170","unstructured":"S.E. Z\u00f6lls, W. Frie\u00df, Protein particle analysis critical factors and new standards, 2013."},{"key":"10.1016\/j.ejpb.2018.08.006_b0175","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jps.22790","article-title":"Classification of protein aggregates","volume":"101","author":"Narhi","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0180","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0022-3549(15)00180-X","article-title":"Subvisible particle content, formulation, and dose of an erythropoietin peptide mimetic product are associated with severe adverse postmarketing events","volume":"105","author":"Kotarek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0185","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bios.2011.09.040","article-title":"Tunable pores for measuring concentrations of synthetic and biological nanoparticle dispersions","volume":"31","author":"Roberts","year":"2012","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.ejpb.2018.08.006_b0190","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12560-013-9122-4","article-title":"A gel filtration-based method for the purification of infectious rotavirus particles for environmental research applications","volume":"5","author":"Farkas","year":"2013","journal-title":"Food Environ. Virol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0195","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3389\/fmicb.2016.01500","article-title":"Quantification of virus particles using nanopore-based resistive-pulse sensing techniques","volume":"7","author":"Yang","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1743-422X-9-265","article-title":"Evaluation of nanoparticle tracking analysis for total virus particle determination","volume":"9","author":"Kramberger","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.ejpb.2018.08.006_b0205","series-title":"Encyclopedia of Nanotechnology","first-page":"1652","article-title":"Nanoparticle Tracking Analysis","author":"Wright","year":"2012"},{"key":"10.1016\/j.ejpb.2018.08.006_b0210","doi-asserted-by":"crossref","first-page":"e0142415","DOI":"10.1371\/journal.pone.0142415","article-title":"Comparative study of non-enveloped icosahedral viruses size","volume":"10","author":"Nikitin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2018.08.006_b0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1773-2247(12)50069-9","article-title":"Evaluation of nanoparticle tracking analysis (NTA) in the characterization of therapeutic antibodies and seasonal influenza vaccines: pros and cons","volume":"22","author":"Patois","year":"2012","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0220","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1021\/ac201006u","article-title":"Viral quantitative capillary electrophoresis for counting intact viruses","volume":"83","author":"Mironov","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejpb.2018.08.006_b0225","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/221418a0","article-title":"Investigating the rabies virus","volume":"221","author":"Hummeler","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2018.08.006_b0230","series-title":"Rabies in the Tropics","first-page":"13","article-title":"Rabies Virus Genome","author":"Crick","year":"1985"},{"key":"10.1016\/j.ejpb.2018.08.006_b0235","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsb.2011.07.003","article-title":"Three dimensional morphology of rabies virus studied by cryo-electron tomography","volume":"176","author":"Guichard","year":"2011","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jviromet.2015.02.006","article-title":"Characterization of vesicular stomatitis virus populations by tunable resistive pulse sensing","volume":"218","author":"Akpinar","year":"2015","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejpb.2018.08.006_b0245","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcis.2013.02.030","article-title":"A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions","volume":"405","author":"Anderson","year":"2013","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0250","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-010-0073-2","article-title":"Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates","volume":"27","author":"Filipe","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2018.08.006_b0255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.virol.2014.06.005","article-title":"Quantitative real-time single particle analysis of virions","volume":"462\u2013463","author":"Heider","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.ejpb.2018.08.006_b0260","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1016\/j.xphs.2016.08.009","article-title":"A comprehensive evaluation of nanoparticle tracking analysis (NanoSight) for characterization of proteinaceous submicron particles","volume":"105","author":"Tian","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2018.08.006_b0265","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1023\/A:1015589926728","article-title":"Kinetics of thermal aggregation of tobacco mosaic virus coat protein","volume":"67","author":"Kurganov","year":"2002","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/j.ejpb.2018.08.006_b0270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0092-1157(81)80022-4","article-title":"An accelerated stability test procedure for lyophilized measles vaccines","volume":"9","author":"Allison","year":"1981","journal-title":"J. Biol. Stand."},{"key":"10.1016\/j.ejpb.2018.08.006_b0275","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-1135(90)90032-Q","article-title":"Comparison of the effect of various chemical stabilizers and lyophilization cycles on the thermostability of a vero cell-adapted rinderpest vaccine","volume":"21","author":"Mariner","year":"1990","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0280","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/JCM.12.4.483-489.1980","article-title":"Influence of residual moisture and sealing atmosphere on viability of two freeze-dried viral vaccines","volume":"12","author":"Precausta","year":"1980","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejpb.2018.08.006_b0285","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejpb.2016.04.010","article-title":"Spectroscopic evaluation of a freeze-dried vaccine during an accelerated stability study","volume":"104","author":"Hansen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2018.08.006_b0290","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/viro.2000.0743","article-title":"Kinetic Analyses of Stability of Simple and Complex Retroviral Vectors","volume":"280","author":"Higashikawa","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.ejpb.2018.08.006_b0295","series-title":"Book Chapter Recent Developments in Prophylactic Immunization","first-page":"114","author":"Nicholson","year":"1989"},{"key":"10.1016\/j.ejpb.2018.08.006_b0300","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","article-title":"G-protein based ELISA as a potency test for rabies vaccines","volume":"46","author":"Chabaud-Riou","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2018.08.006_b0305","unstructured":"ASTM E2834-12, Standard Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA), 2012."},{"key":"10.1016\/j.ejpb.2018.08.006_b0310","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jviromet.2012.06.014","article-title":"A plate-based high-throughput assay for virus stability and vaccine formulation","volume":"185","author":"Walter","year":"2012","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejpb.2018.08.006_b0315","unstructured":"https:\/\/www.yr.no\/place\/Guinea\/Conakry\/Conakry\/statistics.html (accessed on 03\/22\/2018)."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118306696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641118306696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T14:03:26Z","timestamp":1604757806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641118306696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":63,"alternative-id":["S0939641118306696"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.08.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biophysical virus particle specific characterization to sharpen the definition of virus stability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2018.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}